Table: Sumitomo Pharma -2022/23 group results (IFRS)

Sumitomo Pharma

15/05/2023 05:00

May 15 (Reuters)- 
              Sumitomo Pharma Co., Ltd. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                  Year ended      Year ended        Year to          NEXT  
               Mar 31, 2023    Mar 31, 2022     Mar 31, 2024       YEAR    
                  LATEST         YEAR-AGO         COMPANY        COMPANY   
                 RESULTS          RESULT          FORECAST     H1 FORECAST 
  Sales           555.54          560.04           362.00                  
                (-0.8 pct)      (+8.5 pct)      (-34.8 pct)                
  Operating     loss 76.98         60.23         loss 78.00                
                                (-15.4 pct)                                
  Pretax
  Net           loss 74.51         56.41         loss 80.00                
                                (+0.3 pct)                                 
  EPS Basic  loss 187.55 yen    141.99 yen    loss 201.36 yen              
  Ann Div       21.00 yen        28.00 yen          NIL                    
  -Q2 Div       14.00 yen        14.00 yen          NIL                    
  -Q4 Div        7.00 yen        14.00 yen          NIL                    
 
  NOTE - Sumitomo Pharma Co., Ltd.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company.
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4506.T